what is tirzepatide
Tirzepatide (often shortened to tirz) is a synthetic 39-amino-acid peptide that activates two incretin receptors: GIP and GLP-1. In the literature it is also called LY3298176. It is not a triple agonist. Retatrutide, which adds the glucagon receptor, is a different compound.
Peptide Bros lists tirzepatide as a research material. Lot PB-TIRZ-0904, tested September 2026, is published at 99.57% HPLC with 12.74 mg net peptide on the Certificate of Analysis page. The certificate is issued under NorthPeak. Research use only. Not for human or animal consumption.

The pharmaceutical product sold under brand names such as Mounjaro and Zepbound is an approved medicine for specified indications in some countries, including Canada. A research vial is not that product, is not a substitute for it, and is not reviewed by Health Canada for human use.
Tirzepatide at a glance
| Point | Detail |
|---|---|
| Class | Dual agonist: GIP receptor and GLP-1 receptor |
| Length | 39 amino acids, with a C20 fatty diacid linked at lysine-20 |
| Code name | LY3298176 |
| CAS | 2023788-19-2 |
| Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular weight | 4813.5 g/mol (average) |
| Form supplied | Lyophilized powder |
| Current Peptide Bros lot | PB-TIRZ-0904 |
| Published result | 99.57% HPLC, 12.74 mg net peptide, September 2026 |
The fatty-diacid modification is why tirzepatide is discussed as a longer-acting analogue in pharmacokinetic papers. It is also why identity testing has to confirm both the peptide and the modification, not just a purity percentage.
What the research literature examines
Published work on tirzepatide looks at dual-receptor binding, incretin signaling, and metabolic endpoints in preclinical and clinical models. The SURPASS trial program is the body of evidence attached to the approved medicine, not to a research-supply vial. A COA confirms identity and purity of a lot. It does not transfer an approved indication onto that lot.
Useful dividing line when you read a paper: if the material is the Lilly drug product, the findings belong to that product. If the material is a research peptide, the only figures you can cite about the vial in hand are the ones on its certificate.
Tirzepatide vs retatrutide
Buyers in Canada often search these two together. They are not interchangeable.

| Tirzepatide | Retatrutide | |
|---|---|---|
| Receptors | GIP and GLP-1 | GIP, GLP-1, and glucagon |
| Length | 39 amino acids | Separate multi-agonist sequence |
| Status of the named drug | Approved medicine for specified uses in some countries | Investigational in the published literature |
| Peptide Bros lot | PB-TIRZ-0904, 99.57%, 12.74 mg net | PB-RT-0826, 99.38%, 11.06 mg net |
| On this site | Certificate published | Retatrutide 10 mg product page and research overview |
Retatrutide is the right internal link from this post. The overview is at what is retatrutide, and the vial is at retatrutide 10 mg. Cagrilintide is a third metabolic-research compound on the same COA table, lot PB-CG-0726, and it is an amylin analogue, not an incretin agonist.
How to read the certificate
Match the lot on the vial to PB-TIRZ-0904 before use. The row reports HPLC purity and net peptide content. Net peptide is the figure that matters for the amount of compound in the vial. A 99% purity claim without a net-content number does not tell you the fill. Purity on this page is lot-specific. It is not a standing promise for the next fill.
The PDF sits on the Certificate of Analysis page. If the lot on the label is not in that table, email hello@peptidebros.ca before the vial is opened.
Shipping
Orders ship from Canada with tracking. Confirmed before 8:00 a.m. Pacific, Monday to Friday, dispatch the same day. Delivery inside Canada is 1–3 business days. Free shipping over $150 CAD.
Questions
What is tirzepatide? A 39-amino-acid dual agonist of the GIP and GLP-1 receptors, CAS 2023788-19-2, also known as LY3298176.
Is tirzepatide the same as retatrutide? No. Tirzepatide hits two receptors. Retatrutide hits those two plus the glucagon receptor.
For a side-by-side look at the two molecules, see Retatrutide vs. Tirzepatide: Evaluating Multi-Pathway Incretin Models.
Is the Peptide Bros lot tested? Lot PB-TIRZ-0904 tested at 99.57% HPLC with 12.74 mg net peptide in September 2026. The NorthPeak PDF is on the Certificate of Analysis page.
Is research tirzepatide the same as Mounjaro? The molecule is tirzepatide, CAS 2023788-19-2, which is the active ingredient in those approved products. It is sold for research only.
Do you ship inside Canada? Yes. From Canada, tracked, 1–3 business days.
Research and laboratory use only. Not evaluated by Health Canada or the FDA, and not intended to diagnose, treat, cure, or prevent any condition.
Tirzepatide sold by Peptide Bros is a research-grade reference material and is not a Health Canada–authorized drug product. Not for human or veterinary use.
Looking for more peptide research?








